Hypoxic hepatitis as a manifestation of a new coronavirus infection


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The liver is one of the target organs for a new coronavirus infection. The pathogenesis of coronavirus infection is multifactorial, one of the possible causes is hypoxia, which develops due to respiratory failure, which is a distinctive feature of COVID-19. Literature data on the pathogenesis of liver damage in a new coronavirus infection, including liver damage as a result of hypoxia, are presented.

Толық мәтін

Рұқсат жабық

Авторлар туралы

A. Abyzov

Chuvash State University named after I.N. Ulyanov

L. Tarasova

Chuvash State University named after I.N. Ulyanov

E. Busalaeva

Chuvash State University named after I.N. Ulyanov; Institute of Postgraduate Medical Education of the Ministry of Healthcare of Chuvash Republic

Әдебиет тізімі

  1. Metawea M.I., Yousif W.I., Moheb I. COVID 19 and liver: An A-Z literature review. Dig Liver Dis. 2021; 53(2): 146-52. doi: 10.1016/j.dld.2020.09.010.
  2. Amin M. COVID-19 and the liver: Overview. Eur J Gastroenterol Hepatol. 2021; 33(3): 309 doi: 10.1097/MEG.0000000000001808.
  3. Chai X., Hu L., Zhang Y. et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv. 2020. doi: 10.1101/2020.02.03.931766
  4. Idalsoaga F., Ayares G., Arab J.P., Diaz L.A. COVID-19 and indirect liver injury: A narrative synthesis of the evidence. J Clin Transl Hepatol. 2021; 9(5): 760-68. doi: 10.14218/JCTH.2020.00140.
  5. Lightsey J.M., Rockey D.C. Current concepts in ischemic hepatitis. Curr Opin Gastroenterol. 2017; 33(3): 158-63. doi: 10.1097/MOG.0000000000000355.
  6. Premkumar M., Kedarisetty C.K. Cytokine storm of COVID-19 and its impact on patients with and without chronic liver disease. J Clin Transl Hepatol. 2021; 9(2): 256-64. doi: 10.14218/JCTH.2021.00055.
  7. Yang X., Yu Y., Xu J. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8(5): 475-81. doi: 10.1016/S2213-2600(20)30079-5.
  8. Tian D., Ye Q. Hepatic complications of COVID-19 anditstreatment. J Med Virol. 2020; 92(10): 1818-24. doi: 10.1002/jmv.26036.
  9. Feng G., Zheng K.I., Yan Q.Q. et al. COVID-19 and liver dysfunction: Current insights and emergent therapeutic strategies. J Clin Transl Hepatol. 2020; 8(1): 18-24. doi: 10.14218/JCTH.2020.00018.
  10. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 15 (22.02.2022). Минздрав России. Доступ: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/BMP_COVID-19_V15.pdf (дата обращения - 01.03.2022).
  11. Xu Z., Shi L., Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4): 420-22. doi: 10.1016/S2213-2600(20)30076-X.
  12. Zippi M., Fiorino S., Occhigrossi G., Hong W. Hypertransaminasemia in the course of infection with SARS-CoV-2: Incidence and pathogenetic hypothesis. World J Clin Cases. 2020; 8(8): 1385-90. doi: 10.12998/wjcc.v8.i8.1385.
  13. Rey J.R., Caro-Codon J., Rosillo S.O. et al.; CARD-COVID Investigators. Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications. Eur J Heart Fail. 2020; 22(12): 2205-15. doi: 10.1002/ejhf.1990.
  14. Aghemo A., Piovani D., Parigi T.L. et al.; Humanitas COVID-19 Task Force. COVID-19 digestive system involvement and clinical outcomes in a Large Academic Hospital in Milan, Italy. Clin Gastroenterol Hepatol. 2020; 18(10): 2366-68.e3. doi: 10.1016/j.cgh.2020.05.011.
  15. Wang Y., Liu S., Liu H. et al. SARS-CoV-2 infection of the liver directly contributes o hepatic impairment in patients with COVID-19. J Hepatol. 2020; 73(4): 807-16. doi: 10.1016/j.jhep.2020.05.002.
  16. Xu Z., Shi L., Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4): 420-22. doi: 10.1016/S2213-2600(20)30076-X.
  17. Sharma A., Jaiswal P., Kerakhan Y. et al. Liver disease and outcomes among COVID-19 hospitalized patients - A systematic review and meta-analysis. Ann Hepatol. 2021; 21: 100273. doi: 10.1016/j.aohep.2020.10.001.
  18. Del Zompo F., De Siena M., Ianiro G. et al. Prevalence of liver injury and correlation with clinical outcomes in patients with COVID-19: Systematic review with meta-analysis. Eur Rev Med Pharmacol Sci. 2020; 24(24): 13072-88. doi: 10.26355/eurrev_202012_24215.
  19. Huang H., Li H., Chen S. et al. Prevalence and characteristics of hypoxic hepatitis in COVID-19 Patients in the Intensive Care Unit: a first retrospective study. Front Med (Lausanne). 2021; 7: 607206. doi: 10.3389/fmed.2020.607206.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2022

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>